Clinical audit on the use of expensive systemic antifungals in the Besançon University Hospital;Audit clinique des prescriptions d'antifongiques systémiques couteux au centre hospitalier universitaire de Besançon

Medecine et Maladies Infectieuses

Volumn 39, Issue 2, 2009, Pages 125-132

  Raymond, S ^a   Henon, T ^a   Grenouillet, F ^a   Legrand, F ^a   Woronoff Lemsi, M C ^a,b   Hoen, B ^a   Limat, S ^a   Leroy, J ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b INSERM   (France)

Author keywords

Caspofungin; Clinical audit; Health care costs; Liposomal amphotericin B; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; BUDGET; CANDIDIASIS; DRUG COST; DRUG USE; FEBRILE NEUTROPENIA; FINANCIAL MANAGEMENT; HUMAN; MEDICAL AUDIT; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; TREATMENT INDICATION; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CLINICAL AUDIT; DELIVERY OF HEALTH CARE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES;

EID: 59149095821     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2008.09.028     Document Type: Article

References (22)

1. Alfandari S., Leroy O., de Botton S., Yakoub-Agha I., Durand-Joly I., Leroy-Cotteau A., et al. Prise en charge diagnostique et thérapeutique des infections à Aspergillus sp. Chez le patient immunodéprimé. Recommandations du CHRU de Lille - version 4 - novembre 2004. Med Mal Infect 35 (2005) 121-134
2. Kontoyiannis D.P., and Bodey G.P. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 21 (2002) 161-172
3. Vincent J.L., Anaissie E., Bruining H., Demajo W., El-Ebiary M., Haber J., et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24 (1998) 206-216
4. Régnier B. Conférence de consensus commune organisée conjointement par la Sfar, la Spilf et la SRLF avec la participation de la Société française d'hématologie, de la Société française de mycologie médicale et de la Société française de greffe de moelle. 13 Mai 2004, Institut Pasteur, Paris : Prise en charge des candidoses et aspergilloses invasives de l'adulte. J Mycol Med 2004;14:142-146.
5. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
6. Klastersky J. Antifungal therapy in patients with fever and neutropenia. More rational and less empirical?. N Engl J Med 35 (2004) 1445-1447
7. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for the treatment of candidosis. Infectious Diseases Society of America. Clin Infect Dis 38 (2004) 161-189
8. Agence nationale d'accréditation et d'évaluation en santé. L'audit clinique. Bases méthodologiques de l'évaluation des pratiques professionnelles. Paris;1999 (http://www.has-sante.fr).
9. Leroy J., Grenouillet F., Navellou J.C., Fagnoni P., Muret P., Deconinck E., et al. Mise en place de recommandations pour la prise en charge des infections fongiques au CHU de Besançon. J Mycol Med 14 (2004) 185-191
10. Gyssens I.C., Van den Broek P.J., Kullberg B.J., Hekster Y.A., and Van der Meer J.W.M. Optimizing antimicrobial therapy. A method for antimicrobial drug use evaluation. J Antimicrob Chemother 30 (1992) 724-727
11. Marr J.J., Moffet L.H., and Kunin C.M. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 157 (1988) 869-876
12. Edwards J.E., Bodey G.P., Bowden R.A., Büchner T., de Pauw B.E., Filler S.G., et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25 (1997) 43-59
13. Soubani A.O., and Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest 121 (2002) 1988-1999
14. Stevens D.A. Diagnosis of fungal infections: current status. J Antimicrob Chemother 49 (2002) 11-19
15. Wiederhold N.P., Lewis R.E., and Kontoyiannis D.P. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 23 (2003) 1592-1610
16. Scott L.J., and Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67 (2007) 269-298
17. Pappas PG. Treatment guidelines for candidiasis. Interscience conference on antimicrobial agents and chemotherapy;Chicago,USA;2007.
18. Natsch S., Steeghs M.H.M., Hekster Y.A., Meis J.F.G.M., van der Meer J.W.M., and Kullberg B.J. Use of fluconazole in daily practice: still room for improvement. J Antimicrob Chemother 48 (2001) 303-310
19. Pavese P., Ouachi Z., Vittoz J.P., Lebeau B., Foroni L., Allenet B., et al. Revue de pertinence des prescriptions des nouveaux antifongiques systémiques dans un hôpital universitaire. Med Mal Infect 37 (2007) S223-S228
20. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
21. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
22. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347